Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders.

Lauren Julia BrownAlison WepplerPrachi BhaveClara AllayousJ Randall PatrinelyPatrick OttShahneen SandhuAndrew HaydonCeleste LebbeDouglas B JohnsonGeorgina V LongAlexander A MenziesMatteo S Carlino

Published in: Journal for immunotherapy of cancer (2022)

In patients with pre-existing autoimmune disease, not on immunosuppression and advanced melanoma, combination ipilimumab and anti-PD1 has similar efficacy compared with previously reported trials. There is a risk of flare of pre-existing autoimmune disorders, particularly in patients with inflammatory bowel disease and rheumatologic conditions, and patients on baseline immunosuppression.

Keyphrases

multiple sclerosis
patients with inflammatory bowel disease
end stage renal disease
ejection fraction
newly diagnosed
drug induced
prognostic factors
stem cells
patient reported outcomes
patient reported
basal cell carcinoma